Table 1.

Analysis of clinical and sociodemographic features in the studied group of patients

Characteristic	BCT + SLNB n = 69 (%)	BCT + ALND n = 59 (%)	Value of calculated probability
Age	Mean = 63.62 Me = 65 SD = 8.47	Mean = 63.73 Me = 64 SD = 8.60	t = 0.1370 p = 0.8912
Body mass	Mean = 73.90 Me = 69 SD = 13.78	Mean = 73.97 Me = 72 SD = 11.62	t = 0.0297 p = 0.9764
Height	Mean = 1.63 Me = 1.64 SD = 0.05	Mean = 1.61 Me = 1.62 SD = 0.05	t = –2.448 p = 0.0157
BMI	Mean = 27.65 Me = 26.29 SD = 5.11	Mean = 28.46 Me = 28.26 SD = 4.58	t = 0.9389 p = 0.3496
Operated side  L  R	35 (50.72) 34 (49.28)	28 (47.46) 31 (52.54)	χ2 = 0.1358 p = 0.7125
OR  (+)  (–)	60 (86.96) 9 (13.04)	47 (79.66) 12 (20.34)	χ2 = 1.2343 p = 0.2666
PR  (+)  (–)	53 (76.81) 16 (23.19)	41 (69.49) 18 (30.51)	χ2 = 0.8736 p = 0.3499
HER2  (+1)  (+2)  (+3)  (–)	35 (50,72) 0 (0) 5 (7.25) 29 (42.03)	25 (42,37) 2 (3.39) 9 (15.25) 23 (38.98)	χ2 = 4.8074 p = 0.3076
Clinical staging of the disease (cTNM)  T1 N0 M0  T1 N1 M0  T2 N0 M0  T2 N1 M0	51 (73.913) 0 (0) 14 (20.29) 4 (5.797)	43 (72.88) 1 (1.69) 11 (18.64) 4 (6.78)	χ2 = 1.2673 p = 0.7369
Degree of clinical advancement  IA  IIA  IIB	51 (73.913) 14 (20.29) 4 (5.797)	43 (72.88) 12 (20.34) 4 (6.78)	χ2 = 0.0538 p = 0.9735
Number of removed lymph nodes	Mean = 6.07 Me = 3 SD = 7.79	Mean = 9.32 Me = 3 SD = 8.73	Z = 2.1743 p = 0.0297
Number of involved lymph nodes	Mean = 0.61 Me = 0 SD = 1.46	Mean = 1.86 Me = 0 SD = 4.47	Z = 1.0737 p = 0.2829
Adjuvant treatment  CHTH  CHTH + RTH  RTH  HTH	2 (2.90) 25 (36.23) 40 (57.97) 2 (2.90)	3 (5.08) 28 (47.46) 28 (47.46) 0 (0.00)	χ2 = 3.7290 p = 0.2923

M – arithmetic mean; SD – standard deviation; Me – median; BMI – body mass index; L – left; R – right; BCT + SLNB – breast-conserving therapy + sentinel lymph node biopsy; BCT + ALND – breast-conserving therapy + axillary lymph node dissection; OR – oestrogen receptor; PR – progesterone receptor; HER2 – human epidermal growth factor receptor 2; RTH – radiotherapy; CHTH – chemotherapy